Inhibiting Oxidative Phosphorylation In Vivo Restrains Th17 Effector Responses and Ameliorates Murine Colitis

Current understanding of T cell metabolism focuses on activation phases, but little is known about the bioenergetic needs of differentiated T cells. Prior research has shown that T cell function relies on metabolic reprogramming during activation. However, the specific energy requirements of Th17 effector cells remain unclear. This gap motivated investigations into Th17 cell metabolism. No prior work had resolved how Th17 cells meet energy demands during inflammation. Studies on glycolytic and oxidative pathways in Th17 cells are limited. This uncertainty drove the need to explore OXPHOS in Th17 cells. The lack of data on Th17 metabolism in human diseases like Crohn's disease highlights the research need.

The aim of this study was to determine the metabolic profile of Th17 effector cells in vivo. Researchers sought to identify the energy sources used by Th17 cells during inflammation. They focused on whether these cells rely on oxidative phosphorylation or glycolysis. The specific problem addressed was the lack of knowledge about Th17 cell metabolism in disease contexts. The motivation came from observing that Th17 cells are central to inflammatory diseases. The study aimed to test whether OXPHOS inhibition could reduce disease severity. Researchers wanted to connect Th17 metabolism to clinical outcomes. The goal was to explore a potential therapeutic strategy for Th17-driven conditions.

The study used in vivo models of Th17 cell activation and disease progression. Researchers isolated Th17 cells from both mouse and human sources, including Crohn's disease patients. They measured metabolic activity using bioenergetic assays and oxygen consumption rates. The experiments tested the effects of OXPHOS inhibitors on Th17 cell function. They also assessed cytokine production and energy generation in treated cells. The approach included comparing glycolytic and oxidative capacities in Th17 cells. Data analysis focused on identifying metabolic dependencies in these cells. The study combined in vitro and in vivo techniques to validate findings.

Th17 effector cells showed a strong reliance on oxidative phosphorylation for energy production. These cells had limited ability to increase glycolysis under metabolic stress. OXPHOS inhibition reduced cytokine production in Th17 cells. The effect was observed in both mouse and human Th17 cells. Human Th17 cells from Crohn's disease patients also showed this dependency. Inhibiting OXPHOS led to reduced severity in murine colitis models. Psoriasis severity was also reduced in OXPHOS-inhibited models. The findings suggest that Th17 cells are uniquely dependent on OXPHOS.

The study shows that Th17 effector cells depend on OXPHOS for function and cytokine production. This dependency is due to their limited glycolytic capacity. The findings were consistent across mouse and human Th17 cells. OXPHOS inhibition reduced disease severity in murine colitis and psoriasis. The results suggest that targeting OXPHOS could be a therapeutic strategy. The authors propose that Th17 metabolism is a viable target for treatment. The study highlights the importance of in vivo metabolic analysis in immune diseases. These findings support further exploration of OXPHOS in Th17-driven conditions.